Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedMay 20, 2026
DataAggregated Company Financials
Companies20
  • 7D-2.9%
  • 3M-7.3%
  • 1Y-32.0%
  • YTD-13.5%

Over the last 7 days, the Healthcare industry has dropped 3.7%, driven by Novo Nordisk declining 3.6%. Overall the industry is down 30% in 12 months. As for the next few years, earnings are expected to grow by 2.7% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 20 May 2026DKK 1.7tDKK 468.7bDKK 147.0b20.2x11.5x3.6x
Fri, 17 Apr 2026DKK 1.6tDKK 447.1bDKK 129.9b19x12x3.5x
Sun, 15 Mar 2026DKK 1.5tDKK 448.1bDKK 130.1b16.8x11.6x3.4x
Tue, 10 Feb 2026DKK 1.8tDKK 448.0bDKK 134.8b16.3x13.6x4.1x
Thu, 08 Jan 2026DKK 2.1tDKK 453.9bDKK 136.9b17.6x15.6x4.7x
Sat, 06 Dec 2025DKK 1.9tDKK 454.0bDKK 137.0b17.3x13.8x4.1x
Mon, 03 Nov 2025DKK 1.9tDKK 448.0bDKK 141.9b17.2x13.4x4.3x
Wed, 01 Oct 2025DKK 2.0tDKK 447.3bDKK 141.7b17.6x14.2x4.5x
Fri, 29 Aug 2025DKK 2.1tDKK 447.4bDKK 141.7b24.5x14.6x4.6x
Sun, 27 Jul 2025DKK 2.5tDKK 423.1bDKK 124.5b30.1x19.9x5.9x
Tue, 24 Jun 2025DKK 2.5tDKK 423.4bDKK 124.6b30.4x19.7x5.8x
Thu, 22 May 2025DKK 2.5tDKK 424.3bDKK 125.1b24.1x19.9x5.9x
Sat, 19 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b21.8x19.1x5.7x
Mon, 17 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.9x23.5x7x
Wed, 12 Feb 2025DKK 3.2tDKK 408.3bDKK 118.3b28.1x27.1x7.8x
Fri, 10 Jan 2025DKK 3.4tDKK 387.5bDKK 111.3b30.3x30.1x8.6x
Sun, 08 Dec 2024DKK 4.0tDKK 387.3bDKK 111.3b31.3x36.3x10.4x
Tue, 05 Nov 2024DKK 3.9tDKK 372.2bDKK 107.2b33.2x36.5x10.5x
Thu, 03 Oct 2024DKK 4.1tDKK 372.0bDKK 107.1b36.3x38.4x11.1x
Sat, 31 Aug 2024DKK 4.8tDKK 371.8bDKK 107.1b35.5x44.7x12.9x
Mon, 29 Jul 2024DKK 4.5tDKK 355.4bDKK 106.3b35.9x42.1x12.6x
Wed, 26 Jun 2024DKK 5.1tDKK 355.3bDKK 106.2b34.3x48.3x14.5x
Fri, 24 May 2024DKK 4.7tDKK 355.3bDKK 106.2b37.6x44.6x13.3x
Sun, 21 Apr 2024DKK 4.4tDKK 341.3bDKK 99.6b33.3x44.5x13x
Tue, 19 Mar 2024DKK 4.7tDKK 341.2bDKK 99.6b39.2x46.9x13.7x
Thu, 15 Feb 2024DKK 4.3tDKK 340.5bDKK 98.6b34.9x44x12.7x
Sat, 13 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.5x42x11.8x
Mon, 11 Dec 2023DKK 3.5tDKK 320.6bDKK 90.0b33.8x38.9x10.9x
Wed, 08 Nov 2023DKK 3.6tDKK 318.7bDKK 90.3b29.3x40.2x11.4x
Fri, 06 Oct 2023DKK 3.3tDKK 305.5bDKK 82.2b32.7x40.7x11x
Sun, 03 Sep 2023DKK 3.5tDKK 305.4bDKK 82.2b36.7x42x11.3x
Tue, 01 Aug 2023DKK 3.0tDKK 287.2bDKK 75.5b37.6x39.7x10.4x
Thu, 29 Jun 2023DKK 2.9tDKK 287.1bDKK 75.5b39.1x38.3x10.1x
Sat, 27 May 2023DKK 3.1tDKK 287.2bDKK 75.5b41.8x41.4x10.9x
Price to Earnings Ratio

41.4x


Total Market Cap: DKK 3.1tTotal Earnings: DKK 75.5bTotal Revenue: DKK 287.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 30.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.5x which is lower than its 3-year average PE of 30.4x.
  • The 3-year average PS ratio of 8.7x is higher than the industry's current PS ratio of 3.6x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-0.94%
Healthcare-2.85%
Healthcare Services0.35%
Life Sciences-0.56%
Medical Equipment-1.19%
Healthtech-1.59%
Pharma-2.92%
Biotech-4.28%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 646x.
    • Analysts are expecting annual earnings growth of 87.6%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 88% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 12% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AMBU B AmbuDKK 65.454.7%
+DKK 781.1m		-37.2%PE36.3x
CHEMM ChemoMetecDKK 323.801.0%
+DKK 55.7m		-38.2%PE31.8x
BIOPOR BioPortoDKK 1.211.3%
+DKK 7.4m		-15.1%PS14.8x
MONSO MonsensoDKK 0.2527.5%
+DKK 3.5m		4.2%PS1.8x
VIRO ViroGatesDKK 10.402.0%
+DKK 1.9m		26.2%PS10.7x

Latest News

COLO B
DKK 404.40
Coloplast
7D
-0.7%
1Y
-37.7%
Analysis Article • 5h

Some May Be Optimistic About Coloplast's (CPH:COLO B) Earnings

Shareholders appeared unconcerned with Coloplast A/S' ( CPH:COLO B ) lackluster earnings report last week. Our analysis...
AMBU B
DKK 65.45
Ambu
7D
4.7%
1Y
-37.2%
Narrative Update • May 19

AMBU B: Lower P/E Expectations Will Support Future Upside Repricing

Analysts have trimmed their price target on Ambu from DKK 110.34 to DKK 88.80, reflecting a more cautious stance following a downgrade in recent research. The revised target still assumes steady revenue growth and a lower future P/E multiple.
NOVO B
DKK 287.50
Novo Nordisk
7D
-3.0%
1Y
-37.0%
BAVA
DKK 195.70
Bavarian Nordic
7D
-1.4%
1Y
14.1%
Narrative Update • May 16

BAVA: Public Preparedness Contracts And Vaccine Approvals Will Support Higher Future Returns

Analysts have kept their DKK 280 price target for Bavarian Nordic unchanged, pointing to slightly higher assumed revenue growth and profit margins, along with a modestly higher discount rate and a lower future P/E expectation as key inputs behind the refreshed valuation work. What's in the News Bavarian Nordic raised its earnings guidance for 2026, now expecting revenue of DKK 5,500 million to DKK 5,700 million, compared with the earlier range of DKK 5,000 million to DKK 5,200 million.
ZEAL
DKK 299.50
Zealand Pharma
7D
-10.9%
1Y
-29.0%
CHEMM
DKK 323.80
ChemoMetec
7D
1.0%
1Y
-38.2%
GMAB
DKK 1,657.00
Genmab
7D
-3.2%
1Y
23.7%
HLUN B
DKK 40.16
H. Lundbeck
7D
-3.4%
1Y
11.9%
Analysis Article • May 15

Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...
STENO
DKK 1.15
Stenocare
7D
3.1%
1Y
180.5%
VIRO
DKK 10.40
ViroGates
7D
2.0%
1Y
26.2%
DEMANT
DKK 228.20
Demant
7D
-4.0%
1Y
-14.1%
MONSO
DKK 0.25
Monsenso
7D
27.5%
1Y
4.2%
EMBLA
DKK 26.10
Embla Medical hf
7D
-1.5%
1Y
-18.4%
Narrative Update • Apr 30

EMBLA: Share Cancellations And Capital Authorisations Will Support Future Upside

Analysts have trimmed their price target on Embla Medical hf. to DKK 33.30 from DKK 37.40, citing updated assumptions around a slightly higher discount rate, more moderate revenue growth of 8.40% and a lower future P/E of about 21x, while keeping profit margin expectations broadly in line.
BIOPOR
DKK 1.21
BioPorto
7D
1.3%
1Y
-15.1%
SMSMED
DKK 2.90
Scandinavian Medical Solutions
7D
0.3%
1Y
-41.3%